Committee on Public Health Ordinary meeting
10 November 2026
Contents updated on 10 Nov 2026
Legend
Transcript markers
- text Sentence being played
- text Search result
- text Intervention cited by the link you opened
Click a sentence to play the video from that moment. Select text to quote it with the speaker, timestamp and link.
More options
Official source
Offset
Transcript offset
0s
Text size
Export
Replay
Versions of this video
Transcripts may differ slightly from one version to another.
SANT European Parliament
Follow its sittings00:03 - 02:48
Okay colleagues, let's get started. Dear colleagues, our next agenda point this morning is public hearing on development and access to advanced therapy medicinal products in the EU. In today's hearing, we will discuss whether the current EU policy and regulatory environment is fit for advanced therapy medicinal product and transformative therapies and identify structural bottleneck along the development to access pathway. We will explore how the European Union can strengthen its global leadership in the development and manufacturing of organ orphan, sorry, medicines and ATMPs while ensuring sustainable and equitable patient access across member states. To discuss this we have invited leading experts from several countries and fields of expertise.
Today with us, we have Dr. Vanesa Gregorc, director of clinical research and innovation and expert in the Joint Clinical Assessment within the EU Health Technology Assessment framework; Professor Domas Vaitiekus, hematologist, oncologist, associate professor heading the hematopoietic stem cell transplantation unit; Professor Miguel Forte, board of directors member, International Society of Cell & Gene Therapy, chair of the European Advisory Board for the Alliance for Regenerative Medicines and specialist in infectious diseases; and Mrs. Danielle Drachmann, executive director at Ketotic Hypoglycemia International, patient advocacy and policy advisor at the Alliance for Regenerative Medicines and Rare Disease Advocate. I will first give the floor to the first two speakers for a maximum of 8 minutes each.
This will be followed by a first round of reaction from the coordinators and members in the room who ask for the floor. Afterwards we will, I will give the floor to another two speakers for a maximum of 8 minutes each. This will again be followed by a first round of reaction from the coordinators and members. Dr. Gregorc, the floor is yours for 8 minutes, please.
02:48 - 03:11
Vanesa Gregorc
Oncologue médicale et responsable de la recherche clinique et de l’unité de phase 1 au National Cancer Institute de Candiolo
Thank you very much. Chair, honorable members, ladies and gentlemen, good morning. Thank you for inviting me. I am Vanesa Gregorc, medical oncologist, and I also doing research since 95. I lead clinical research and phase one unit at National Cancer Institute at Candiolo, Turin, Italy. And I also speak on behalf of European Comprehensive Cancer Centres.
The rest of the transcript is for Pro customers
Unlock the full transcript, chat, and every analysis feature with Polyfact Pro.
The video itself stays free to watch, in full, no account needed.